-
Notifications
You must be signed in to change notification settings - Fork 49
New issue
Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.
By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.
Already on GitHub? Sign in to your account
How to present drug discovery efforts against 3CLpro, PLpro, RdRP, etc #45
Comments
Define "a whole bunch." Why would having so many structures and molecules be bad? |
Would it be sufficient to have both a "single structure" and "collection of related structures" entry type? For example, the first Mpro structure and the DiamondMX structures, subdivided into active site noncovalent, noncovalent, and dimer interface. Same with molecules: "single molecule of interest" and "collection/dataset of molecules of interest"? |
Im not sure how this would work in practice. Since every structure and molecule are their own YAML entry. There is a far amount of logic we can apply, but I'd want to make sure we get it right the first time since this will be a pretty big overhaul to the data structures and the cross-linking system |
@Lnaden : I just meant to treat a "collection" as a single entity, with additional fields that indicate it is a collection and specify either the independent elements or the most important element(s) of the collection. |
Not a bug, I just didn't see a format that looked right
There are a WHOLE bunch of 3CLpro (Mpro, Main Protease, nsp5) structures. And potentially a WHOLE BUNCH of molecules that will target it. I think it's worth thinking about the best way to curate and share this data.
My current idea would be to just:
This could be expanded to PLpro (nsp3) and RdRP (nsp12) in a similar fashion.
The text was updated successfully, but these errors were encountered: